Recovering scientist turned early stage VC A biotech optimist fighting gravity

Frameworks for Decision-Making & Lessons Learned from “Failing Fast”
April 17, 2025

By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC Drug discovery and development is a long, and often fraught, journey – it typically takes more than a decade to progress from idea

Leave a comment

Biotech Venture Creation: The Benefits Of Scarcity
April 8, 2025

The equity markets have collapsed in 2025, the IPO window is closed, the FDA is in turmoil, the NIH is being gutted… and it’s a great time to start new biotech companies. Why?  Because there are so few being created

Leave a comment

Strategic Infrastructure in a Fragmenting World: Biotech in the Transition Zone
April 8, 2025

By Jason Campagna, CMO of Q32 Bio, as part of the From The Trenches feature of LifeSciVC We’re entering a phase shift in biotech—one that extends beyond molecules, pipelines, or even platforms. Tariff escalations, supply chain fractures, and a reassertion

Leave a comment

The Biotech Juggling Act: Keeping all the Balls in the Air
March 20, 2025

“When the going gets tough, the tough get going” By Ram Aiyar, CEO of Korro Bio, as part of the From the Trenches feature of LifeSciVC. It has been quite a start to the 2025 year. The sentiment around biotech

Leave a comment

 The Sweetest Thing
March 12, 2025

By Arthur Tzianabos, CEO of Lifordi Immunotherapeutics, as part of the From The Trenches feature of LifeSciVC Given everything going on in our world right now, I’ve been thinking a lot about the state of biotech innovation…particularly as we wrestle

Leave a comment

Pitfalls Of The Scarcity Mindset
February 28, 2025

By Ankit Mahadevia, serial biotech entrepreneur and former CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC I recently had an illuminating discussion with a seed-stage biotech Founder, who was reflecting after a hard and

Leave a comment

Dancing with the DGC: Structural Biology Meets Muscular Dystrophy
February 18, 2025

By Cody Tranbarger, EIR at Atlas Venture, as part of the From The Trenches feature of LifeSciVC For decades, muscular dystrophy has stubbornly persisted among the most intractable categories of human disease. Despite recent progress with AAV Gene Therapy and

Leave a comment

A New Wave of Therapeutic Innovation Through Targeting Transcription Factors
February 5, 2025

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC In the perpetual and never-ending race by the healthcare sector to unearth new approaches and therapeutics to address disease, one area in which

Leave a comment

A Tale of Two Sentiments: JPM 2025
January 21, 2025

By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC “It was the best of times, it was the worst of times…” Another JPM is behind us, and while much of the small

Leave a comment

Atlas XIV And Reflections On The VC Math Problem
December 5, 2024

Today we announced the closing of Atlas Venture Fund XIV, a $450M investment vehicle focused exclusively on early stage biotech investing. With the closing of Fund XIV, we’re privileged to be able to continue backing innovative new biotech companies for

Leave a comment

Atlas Venture 2024 Year In Review
November 18, 2024

“May you live in interesting times” – or so goes the phrase. In 1966, RFK Jr’s father famously used that quote to capture the turbulence of the times, and continued: “Like it or not, we live in interesting times. They

Leave a comment

Biotech Risk Cycles: Assets And Platforms
October 28, 2024

Today’s market likes products. Platforms aren’t in vogue anymore. Investors, especially in the public markets, only want late stage de-risked assets. Pharma only seems to be buying these kinds of asset. VCs need to focus on clinical stage companies. Or

Leave a comment



Verified by ExactMetrics